Dr. Guenther Eissner This is Me

Education

 Web References

1. 1. www.sec.gov

   www.sec.gov/Archives/edgar/dat - [Cached]

   Published on: 5/30/2006   Last Visited: 5/31/2006

   Dr. Guenther Eissner
   ...
   Dr. Guenther Eissner has served as our Senior Vice-President, Chief of Biology Research Laboratory since August 2004. Since May 1998, Dr. Eissner has served as the Senior Scientific Group Leader of the Lab for Experimental Allogeneic BMT in the Department of Hematology and Oncology at the University of Regensburg, Germany. From October 1997 to April 1998, Dr. Eissner was the Group Leader at the Medical Clinic III, Ludwig-Maximilians-University of Munich, Germany. From 1992 to September 1997, he worked at the Institute for Clinical Molecular Biology of the GSF-Research Center for Environment and Health, in Munich, Germany. Prior to 1992, Dr. Eissner served as group leader at the Medical Clinic III, Ludwig-Maximilians-University of Munich, Germany. Dr. Eissner received a degree in Human Biology (Theoretical Medicine) from Philipps-University of Marburg, Germany, a Masters degree from the Max Planck-Institute for Biochemistry at Martinsried, Germany, and a Ph.D. from the Institute for Immunology of the Ludwig-Maximilians-University of Munich, Germany.

2. 2. Genetic Engineering News - The Leading Publication in Biotechnology

   www.genengnews.com/news/bnitem - [Cached]

   Published on: 8/9/2005   Last Visited: 8/9/2005

   Gentium S.p.A. (AMEX: GNT) (the "Company") announced that earlier today in Sydney, Australia, Dr. Guenther Eissner, Ph.D, Chief of the Molecular Biology Research Laboratory for Gentium, presided over a poster presentation at the XXth Annual Congress of the International Society on Thrombosis and Hemostasis.

3. 3. Gentium to Present at Angiogenesis in Cancer and Vascular Disease Congress: Financial News - Yahoo! Finance

   biz.yahoo.com/bw/060202/200602 - [Cached]

   Published on: 2/2/2006   Last Visited: 2/2/2006

   VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Feb. 2, 2006--Gentium S.p.A. (AMEX:GNT - News; the "Company") today reported that on February 7, 2006, Guenther Eisser, Chief of Biology Research for Gentium, will present a poster entitled, "Defibrotide, an endothelium stabilizing drug, has anti-angiogenic properties in vitro and in vivo," at the Angiogenesis in Cancer and Vascular Disease Congress being held in Miami, Fla. from February 4-8, 2006.
   
   The anti-angiogenic potential of Defibrotide was tested in-vitro using the sprouting of cells from the rat aortic ring in Matrigel(TM) and a kit with human microvascular endothelial cells forming vessel-like structures across a layer of dermal fibroblasts (AngioKit(TM)).
   ...
   Dr. Eisser concluded, "Our data suggest that while Defibrotide is known for its endothelium-protecting function, it also inhibits tumor blood vessel formation and thus should be considered for further testing as an anti-cancer agent, either alone or in combination with other drugs."
   
   Commenting on the presentation of this data, Dr. Laura Ferro, chairman and chief executive officer of Gentium, stated, "We are pleased to present the work of Dr. Eisser and his colleagues as it expands our knowledge of Defibrotide's possible pharmacodynamic actions, thereby elucidating the potential therapeutic benefits that might be tested in a variety of cancer and vascular indications.